![Benedikte Hatz](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Benedikte Hatz
Director Ejecutivo en TeGenero AG .
Cargos activos de Benedikte Hatz
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
TeGenero AG
![]() TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Director Ejecutivo | 01/08/2001 | - |
Historial de carrera de Benedikte Hatz
Formación de Benedikte Hatz.
Technische Universität München | Doctorate Degree |
Estadísticas
Internacional
Alemania | 3 |
Operativa
Chief Executive Officer | 1 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
TeGenero AG
![]() TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Health Technology |
- Bolsa de valores
- Insiders
- Benedikte Hatz
- Experiencia